Page 97 - Revista Argentina de Transfusión 2-2019

5. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, 13. O’Brien SF, Yi QL, Fan W, Scalia V, Goldman M,Fearon MA.
Preston S, et al. Report of the Interorganizational Task Force on Residual risk of HIV, HCV and HBV in Canada. Transfus
Nucleic Acid Amplification Testing of Blood Donors. Transfu- Apheresis Sci 2017; 56:389-391.
sion 2000; 40:143–159. 14. Alvarez M, Oyonarte S, Rodríguez PM, Hernández JM. Esti-
6. Stramer SL, Glynn SA, Kleinman, SH, Strong DM, Caglioti S, mated risk of transfusion-transmitted viral infections in Spain
Wright DJ, et al. Detection of HIV-1 and HCV Infections among Transfusion 2002; 42:994-998.
Antibody-Negative Blood Donors by Nucleic Acid–Amplifica- 15. Laperche S, Tiberghien P, Roche-Longin C, Pillonel J: Fifteen
tion Testing. N Engl J Med 2004; 351:760-768. years of Nucleic Acid Testing in France: Results and lessons.
7. Dodd RY, Notari EP, Stramer SL. Current prevalece and inci- Transfusion Clinique et Biologique 2017; 24:182-188.
dence of infectious diseases markers and estimated window- 16. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR,
period risk in the American Red Cross blood donor population. Jungbauer C et al. International survey on NAT testing of blood
Transfusion 2002; 42:975-979. donations: expanding implementation and yield from 1999 to
8. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright 2009. Vox Sanguinis 2012; 102: 82–90.
DJ et al. A new strategy for estimating risks of transfusion- 17. Wendel S, Acevedo ME, Baungarten C, Benati FJ, Bravo A,
transmitted viral infections based on rates of detection of re- Camacho B, et al. The ISBT Working Party for Transfusion-Trans-
cently infected donors. Transfusion 2005; 45: 254-264 mitted Infectious Disease (WP-TTID) Survey for NAT testing in
9. Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus Latin America. Vox Sanguinis 2012; 103 (Suppl.1):10.
testing by minipool nucleic acid testing: does it improve blood 18. Chiera AO, Remesar MC, Blejer JL, Punzi ML, Rey JA, Livellara
safety? Transfusion 2013; 53:2449-2458. B, et al.Pruebas NAT en bancos de sangre de Argentina:
10. Padilla A, Nuebling CM, Laperche S, Lelie N, Nick S, Preussel K Resultados y estado actual. Rev Arg Transf 2018; 44:9-14.
et al. Guidelines on estimation of residual risk of HIV, HBV or 19. Blanco S, Balangero MC, Valle MC, Montini OL, Carrizo
HCV infections via cellular blood components and plasma. WHO LH, Gallego SV. Usefulness of nucleic acid testing to reduce
Technical Report Series 2017; 1004: 163-196. risk of hepatitis B virus transfusion-transmitted infection in
11. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW Argentina: high rate of recent infections. Transfusion 2017;
et al. Comparative sensitivity of HBV NATs and HBsAg assays 57:816-822
for detection of acute HBV infection. Transfusion 2003; 43:788-
798.
12. Zou S, Musavi F, Notari EP, Stramer SL, Dodd RY. Prevalence,
incidence, and residual risk of major blood-borne infections
among apheresis collections to the American Red
Cross Blood Services, 2004 through 2008. Transfusion 2010;
50:1487-1494.

Estimación del riesgo residual para VIH, VHB y VHC Vol. XLV / N° 2 / 2019 Asociación Argentina Pág. 181
en un Centro Regional de Hemoterapia en Ciudad Págs. 175 / 181 de Hemoterapia,
de Buenos Aires. Inmunohematología
y Terapia Celular